TRVN:OTCMKTS
트리베나
US$0.066
0.00%
(0.00) 1D
10월 12일, 오후 2시 57분 26초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoTRVN의 주요 통계 생성 중...
시가총액
5.70만
평균 거래량
210.00
거래량
23.00
52주 최고가
US$1.50
52주 최저가
US$0.00
베타
1.07
유통 주식수
86.40만
직원 수
23
시가총액
5.70만
평균 거래량
210.00
거래량
23.00
52주 최고가
US$1.50
52주 최저가
US$0.00
베타
1.07
유통 주식수
86.40만
직원 수
23
뉴스 기사
웹 소스 및 뉴스 파트너 제공
ad-hoc-news.de
·
5시간 전
MarketBeat estimates results for Trevena stock
프로필
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
트리베나에 관한 정보